Towards Good Simulation Practice – An interview of Luca Emili and Prof. Marco Viceconti

During the 2020 Avicenna Day many experts from all over the world talked about the need for Good Simulation Practice, a term coined by the Avicenna Alliance taking inspiration from the Good Clinical Practice typical of the clinical world to bring similar rules to Modeling & Simulation applied to the Pharmaceutical and Medical Devices industries.

Good Simulation Practice is progressively becoming a buzz word in the international scientific community while this concept could still lead to different interpretations; but where do we stand on creating and spreading GSP?

Let’s ask Luca Emili, Leader of the Good Simulation Practice Task Force at the Avicenna Alliance and CEO of InSilicoTrials: “This initiative was born to ensure that the results of computer modeling and simulation (CM&S) would be universally accepted as is the case of clinical trials. There is a strong need today – a requirement that also emerged from various researches – to have clearly defined rules and accepted regulations, since there is no document similar to that of Good Clinical Practice in the field of digital simulation. Our first goal is to raise awareness and start defining the context of use (COU) or how simulation can be used here. Essentially, Modeling & Simulation aims to Reduce, Refine and (in some cases) Replace (3Rs) in vitro and in vivo (animal and human) experiments”.